



## Moving translational immunology forward through public-private partnership

A symposium organised by the **Innovative Medicines Initiative (IMI)** at the **15th International Congress of Immunology** 

| Room Space 1                         | 15:10 - 16:40         |
|--------------------------------------|-----------------------|
| MiCo Milano Congressi, Milan (Italy) | Monday 26 August 2013 |

| 15:10 – 15:15 | Welcome and introduction   |
|---------------|--|
|               | <i>Luciano Adorini</i> , President of the 15th International Congress of<br>Immunology                       |
| 15:15 – 15:30 | IMI: opportunities and challenges for immunologists  |
|               | <i>Michel Goldman</i> , Executive Director of the Innovative Medicines<br>Initiative (IMI), Belgium          |
| 15:30 – 15:45 | Enhancing discovery through new models of collaboration with academia and industry                           |
|               | Jeffrey A. Bluestone, A.W. And Mary Margaret Clausen<br>Distinguished Professor, UC San Francisco, USA       |
| 15:45 – 16:00 | Translating inflammatory understanding towards patient benefit: lessons from anti-TNF therapy                |
|               | <i>Marc Feldmann</i> , Head of Kennedy Institute of Rheumatology,<br>University of Oxford, UK                |
| C             | Open innovation: a new paradigm for industry-academia collaboration  |
|               | <b>Paul-Peter Tak</b> , Senior Vice President;<br>Head, ImmunoInflammation Therapy Area, GlaxoSmithKline, UK |
| 16:15 – 16:40 | Panel Discussion / Questions & Answers<br>chaired by Luciano Adorini   |

